List view / Grid view
8 February 2016 | By Victoria White
Biogen’s new membership follows the launch of the new CTTV Target Validation Platform, which helps researchers identify therapeutic targets for new medicines...
4 February 2016 | By Victoria White
Researchers showed that virus-like particles carrying LXY-30 could home in on breast cancer cells both in a laboratory dish and in a mouse model...
28 January 2016 | By Victoria White, Digital Content Producer, Drug Target Review
2015 was an exciting year for the drug discovery industry. Here we look at a selection of stories that particularly stood out for us…
28 January 2016 | By Victoria White
The ADDoPT project addresses the key challenge of getting new innovative medicines to market in the quickest and most cost-effective way...
27 January 2016 | By Victoria White
The study marks the first time researchers have replaced a defective gene associated with a sensory disease in stem cells that were derived from a patient's tissue...
26 January 2016 | By Victoria White
Scientists from UTSW have crafted synthetic "dendrimer" nanoparticles that are able to provide a tumour-suppressing effect without further damaging the liver or neighbouring tissue...
21 January 2016 | By Hans Fliri PhD, Chairman, Cypralis
Here, Dr Hans Fliri, Chairman and CEO of Selcia and Chairman of Cypralis, presents a strong case for targeting mitochondrial cyclophilin D to prevent progression of chronic neurodegenerative diseases...
21 January 2016 | By Victoria White
The Lead Discovery Centre (LDC) and Roche have announced that they are to collaborate to identify and leverage innovative therapeutic opportunities that address diseases of unmet medical need...
21 January 2016 | By Victoria White
The researchers have announced a major improvement in CRISPR-Cas9 technology that achieves an unprecedented success rate of 60% when replacing a short stretch of DNA with another...
20 January 2016 | By Victoria White
Through the Phenotypic Discovery Initiative (PDi), partners will build robust, disease-relevant phenotypic assays with a focus on human-derived systems with the aim of identifying new drug targets and hit molecules.
19 January 2016 | By Philippe Villain-Guillot, CEO, Nosopharm
Philippe Villain-Guillot, CEO, Nosopharm, discusses antimicrobial resistance and the challenges facing antibacterial drug discovery and development...
19 January 2016 | By Victoria White
The largest analysis of breast cancer cell function to date suggests dozens of new uses for existing drugs, new targets for drug discovery, and new drug combinations...
18 January 2016 | By Victoria White
Centuari has also announced that it has appointed Dr Clive Dix as Chairman and secured the first tranche of a £3M raise to develop its first lead candidate...
13 January 2016 | By Oxford Global
Oxford Global Conferences are proud to present the successful 17th Annual Drug Discovery Leaders Summit and co-located 4th Annual Discovery Chemistry & Drug Design Congress taking place on the 13th & 14th June in Berlin...
13 January 2016 | By Victoria White
Boehringer Ingelheim and Arena Pharmaceuticals have signed an exclusive agreement to conduct joint research to identify drug candidates for psychiatric diseases...
